PT91808A - Processo para a preparacao de anticorpos monoclonais hibridos e de composicoes farmaceuticas que os contem - Google Patents

Processo para a preparacao de anticorpos monoclonais hibridos e de composicoes farmaceuticas que os contem

Info

Publication number
PT91808A
PT91808A PT91808A PT9180889A PT91808A PT 91808 A PT91808 A PT 91808A PT 91808 A PT91808 A PT 91808A PT 9180889 A PT9180889 A PT 9180889A PT 91808 A PT91808 A PT 91808A
Authority
PT
Portugal
Prior art keywords
hibrid
preparing
pharmaceutical compositions
monoclonal antibodies
compositions containing
Prior art date
Application number
PT91808A
Other languages
English (en)
Other versions
PT91808B (pt
Inventor
Suaumu Iwasa
Tomofumi Kurorawa
Yukio Toyoda
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of PT91808A publication Critical patent/PT91808A/pt
Publication of PT91808B publication Critical patent/PT91808B/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46Hybrid immunoglobulins
    • C07K16/468Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6815Enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • A61K47/6879Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the immunoglobulin having two or more different antigen-binding sites, e.g. bispecific or multispecific immunoglobulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
PT91808A 1988-09-27 1989-09-26 Processo para a preparacao de anticorpos monoclonais hibridos e de composicoes farmaceuticas que os contem PT91808B (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP24354488 1988-09-27
JP30192588 1988-11-28
JP6294089 1989-03-14
JP16487389 1989-06-27
JP20893689A JP3177776B2 (ja) 1988-09-27 1989-08-11 ハイブリッドモノクローナル抗体,抗体産生ポリドーマおよび抗体含有薬剤

Publications (2)

Publication Number Publication Date
PT91808A true PT91808A (pt) 1990-03-30
PT91808B PT91808B (pt) 1995-05-31

Family

ID=27523741

Family Applications (1)

Application Number Title Priority Date Filing Date
PT91808A PT91808B (pt) 1988-09-27 1989-09-26 Processo para a preparacao de anticorpos monoclonais hibridos e de composicoes farmaceuticas que os contem

Country Status (15)

Country Link
US (1) US5506135A (pt)
EP (1) EP0363712B1 (pt)
JP (1) JP3177776B2 (pt)
KR (1) KR900004351A (pt)
CN (1) CN1041783A (pt)
AR (1) AR242832A1 (pt)
AT (1) ATE140930T1 (pt)
AU (1) AU628857B2 (pt)
DE (1) DE68926899T2 (pt)
DK (1) DK474189A (pt)
FI (1) FI894551A (pt)
HU (1) HUT55445A (pt)
IL (1) IL91649A (pt)
NO (1) NO893818L (pt)
PT (1) PT91808B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030068322A1 (en) * 1988-04-18 2003-04-10 Immunomedics, Inc. Methods of antibody-directed enzyme-prodrug therapy
TW212184B (pt) * 1990-04-02 1993-09-01 Takeda Pharm Industry Co Ltd
JPH0576385A (ja) * 1990-12-18 1993-03-30 Takeda Chem Ind Ltd キメラ抗体およびその用途
AP257A (en) * 1991-04-26 1993-06-03 Surface Active Ltd A method of releasing an antigen from an antibody and methods for their use in diagnosis and therapy.
WO2015053381A1 (ja) * 2013-10-10 2015-04-16 幸成 加藤 抗ポドプラニン抗体
SG11201910113PA (en) * 2017-05-02 2019-11-28 Nat Cancer Center Japan Plasmin-cleavable anti-insoluble fibrin antibody-drug conjugate

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474893A (en) * 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4714681A (en) * 1981-07-01 1987-12-22 The Board Of Reagents, The University Of Texas System Cancer Center Quadroma cells and trioma cells and methods for the production of same
ES8504461A1 (es) * 1982-04-12 1985-04-16 Hybritech Inc Un procedimiento para obtener un polidoma.
US4916070A (en) * 1986-04-14 1990-04-10 The General Hospital Corporation Fibrin-specific antibodies and method of screening for the antibodies
EP0241907A3 (en) * 1986-04-14 1989-09-13 The General Hospital Corporation Heterobifunctional antibodies and method of use

Also Published As

Publication number Publication date
DK474189A (da) 1990-03-28
NO893818L (no) 1990-03-28
IL91649A0 (en) 1990-04-29
KR900004351A (ko) 1990-04-12
US5506135A (en) 1996-04-09
FI894551A0 (fi) 1989-09-26
DE68926899T2 (de) 1997-01-02
DE68926899D1 (de) 1996-09-05
NO893818D0 (no) 1989-09-26
FI894551A (fi) 1990-03-28
IL91649A (en) 1994-10-21
HUT55445A (en) 1991-05-28
DK474189D0 (da) 1989-09-26
AU4174789A (en) 1990-04-05
ATE140930T1 (de) 1996-08-15
EP0363712A3 (en) 1990-08-16
AR242832A1 (es) 1993-05-31
EP0363712A2 (en) 1990-04-18
AU628857B2 (en) 1992-09-24
JP3177776B2 (ja) 2001-06-18
JPH03103175A (ja) 1991-04-30
PT91808B (pt) 1995-05-31
EP0363712B1 (en) 1996-07-31
CN1041783A (zh) 1990-05-02

Similar Documents

Publication Publication Date Title
PT81746B (pt) Processo para a preparacao de peptido-aldeidos e de composicoes farmaceuticas que os contem
PT84569B (pt) Processo para a preparacao de tiazepinas e de composicoes farmaceuticas que os contem
PT89009A (pt) Processo para a preparacao de novos derivados de fluorocitidina e composicoes farmaceuticas que os contem
PT78732A (pt) Processo para a preparacao de 13 alpha-alquilgonanos e de composicoes farmaceuticas que os contem
PT88914A (pt) Processo para a preparacao de polipeptidos e de composicoes farmaceuticas que os contem
PT92502A (pt) Processo para a preparacao de compostos de pirimidina e de composicoes farmaceuticas que os contem
PT90836A (pt) Processo para a preparacao de derivados de aminoacidos e de composicoes farmaceuticas que os contem
PT87913A (pt) Processo para a preparacao de derivados de benzopirano e de composicoes farmaceuticas que os contem
PT89899A (pt) Processo para a preparacao de novos derivados de aminoacidos e de composicoes farmaceuticas que os contem
PT93600A (pt) Processo para a preparacao de pteridin-4(3h)-onas e de composicoes farmaceuticas que os contem
PT84258B (pt) Processo para a preparacao de anticorpos monoclonais humanos de proteccao cruzada e de composicoes farmaceuticas que os contem
PT93060A (pt) Processo para a obtencao de derivados de piridazina e de composicoes farmaceuticas que os contem
PT80246B (pt) Processo para a preparacao de novos derivados de cefalosporina e de composicoes farmaceuticas que os contem
PT81659B (pt) Processo para a preparacao de aminoacil-labdanos e de composicoes farmaceuticas que os contem
PT82984B (pt) Processo para a preparacao de derivados de poli-4-aminopirrole-2-carboxamido e de composicoes farmaceuticas que os contem
PT89234A (pt) Processo para a preparacao de novos compostos de amonio e de composicoes farmaceuticas que os contem
PT91122A (pt) Processo para a preparacao de novos derivados amidinicos e guanidinicos e de composicoes farmaceuticas que os contem
PT92391A (pt) Processo para a sintese de nitro-imidazois e de composicoes farmaceuticas que os contem
PT93290A (pt) Processo para a preparacao de novos eteres heterociclicos e de composicoes farmaceuticas que os contem
PT87115A (pt) Processo para a preparacao de derivados da dihidropiridazinona e de composicoes farmaceuticas que os contem
PT92264A (pt) Processo para a preparacao de 14alfa, 17alfa-etano-estratrienos e de composicoes farmaceuticas que os contem
PT87090A (pt) Processo para a preparacao de derivados de imidazopiridinas e de composicoes farmaceuticas que os contem
PT98697A (pt) Processo para a preparacao de compostos macrociclicos e de composicoes farmaceuticas que os contem
PT89501B (pt) Processo para a preparacao de novos gliceridos de amino-acidos e de composicoes farmaceuticas que os contem
PT82960B (pt) Processo para a preparacao de derivados de 6-amino-pirimidina 5-substituidos e de composicoes farmaceuticas que os contem

Legal Events

Date Code Title Description
FG3A Patent granted, date of granting

Effective date: 19941121

MM3A Annulment or lapse

Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

Effective date: 19960531